Navigation Links
Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Date:10/12/2010

AURORA, Ontario, Oct. 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.   These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.  

The Company plans to conduct a Phase I study in the U.S. in patients with refractory solid tumors and a  Phase I/II, multi-arm safety and preliminary efficacy study in patients with stage III/IV non-small cell lung cancer in Poland.  It intends to use the findings from its GLP toxicology studies to complete the necessary protocol designs and other supportive documentation, as final steps in preparing its U.S. Phase I IND and its Polish Phase I/II CTA dossiers.  As a result of some delays in completing its GLP toxicology studies, Helix now expects these IND/CTA submissions to be made in its second rather than its first quarter of fiscal 2011.  

"We are very pleased to reach this important clinic-enabling milestone in our L-DOS47 development program," said John Docherty, Helix president and COO.  "Having completed these studies, Helix believes it now has a sufficient preclinical pharmacology and toxicology database to support human clinical testing with this important new drug candidate.  Helix is committed to completing these submissions as soon as possible, as it is no longer waiting for any further preclinical study findings before doing so."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidates. Helix is listed on the Toronto, NYSE Amex and Frankfurt Stock Exchanges under the symbol "HBP".  For more information, please visit www.helixbiopharma.com. For further information contact:Robert Flamm, Ph.D.Russo Partners, LLCTel: (212) 845-4226Email: robert.flamm@russopartnersllc.com  www.russopartnersllc.com   This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements") regarding the intended use by Helix BioPharma Corp. ("Helix" or the "Company") of GLP toxicology study findings for L-DOS47 and its belief regarding their support for human clinical testing, its plans to conduct clinical trials of L-DOS47, its expected timing of L-DOS47 IND/CTA submissions, and its drug product development, which statements and information can be identified by the use of forward looking terminology such as "plans", "intends", "expects", "believes",  "committed to" and "developing".  Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.  Certain material factors or assumptions applied in making forward-looking statements include without limitation, that Helix's toxicology studies will support human testing, Helix's receipt of regulatory approvals and necessary funding, the expeditious completion of its IND and CTA dossiers, and the safety and efficacy of Helix's drug candidates.  Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all; uncertainty whether the Company's drug candidates will be successfully developed and commercialized; the need for further regulatory approvals, which are not assured; the Company's dependence on performance by third parties; uncertainty whether the Company's planned clinical trials referred to in this news release will be approved, conducted or achieve expected results; product liability and insurance risks; uncertainties related to research and development, including manufacturing risks; intellectual property risks; and the risk of changes in business strategy or development plans. Investors should consult the Company's quarterly and annual filings, including its latest Form 20-F, with the Canadian and U.S. securities commissions at www.sedar.com and at www.sec.gov for additional information on these and other risks and uncertainties which may affect the Company. Investors are cautioned against placing undue reliance on forward-looking statements. Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, assumptions, opinions or expectations change, except as required by law. 


'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix Biopharma Closes $11.4 Million Private Placement
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
6. Helix BioPharma Announces Q1 2009 Financial Results
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Announces Q2 2009 Financial Results
11. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):